CLINICAL TRIALS PROFILE FOR SOLABEGRON
Clinical Trials for Solabegron
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00343486 ↗ | Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms | Completed | GlaxoSmithKline | Phase 2 | This study will test the effectiveness and safety of two doses of solabegron against placebo in reducing the symptoms of overactive bladder. |
| NCT00394186 ↗ | A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS) | Completed | GlaxoSmithKline | Phase 2 | This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, will relieve IBS pain or discomfort and associated symptoms in IBS patients. |
| NCT00401479 ↗ | A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers | Completed | GlaxoSmithKline | Phase 1 | This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, retards the emptying of the colon and increases total colonic transit time. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Solabegron
Condition Name
Clinical Trial Locations for Solabegron
Trials by Country
Clinical Trial Progress for Solabegron
Clinical Trial Phase
Clinical Trial Sponsors for Solabegron
Sponsor Name
